JP Morgan Chase’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,064
| Closed | -$1.21K | – | 7510 |
|
|
2025
Q4 | $1.21K | Buy |
12,064
+4,433
| +58% | +$2.82K | ﹤0.01% | 7003 |
|
|
2025
Q3 | $4.62K | Buy |
7,631
+5,647
| +285% | +$2.66K | ﹤0.01% | 6788 |
|
|
2025
Q2 | $617 | Sell |
1,984
-51,923
| -96% | -$20.1K | ﹤0.01% | 6674 |
|
|
2025
Q1 | $26.4K | Buy |
53,907
+2,357
| +5% | +$1.39K | ﹤0.01% | 6072 |
|
|
2024
Q4 | $44.1K | Buy |
51,550
+3,237
| +7% | +$20.3K | ﹤0.01% | 6057 |
|
|
2024
Q3 | $411K | Buy |
48,313
+7,175
| +17% | +$42.3K | ﹤0.01% | 5032 |
|
|
2024
Q2 | $192K | Sell |
41,138
-137,786
| -77% | -$652K | ﹤0.01% | 5185 |
|
|
2024
Q1 | $1.22M | Buy |
178,924
+131,991
| +281% | +$593K | ﹤0.01% | 4200 |
|
|
2023
Q4 | $157K | Buy |
46,933
+46,545
| +11,996% | +$116K | ﹤0.01% | 5518 |
|
|
2023
Q3 | $966 | Sell |
388
-26,715
| -99% | -$44K | ﹤0.01% | 6650 |
|
|
2023
Q2 | $34.7K | Sell |
27,103
-48,643
| -64% | -$64.5K | ﹤0.01% | 5801 |
|
|
2023
Q1 | $61K | Buy |
75,746
+75,358
| +19,422% | +$74.2K | ﹤0.01% | 5636 |
|
|
2022
Q4 | $0 | Sell |
388
-1,646
| -81% | -$1.3K | ﹤0.01% | 6518 |
|
|
2022
Q3 | $2K | Buy |
2,034
+812
| +66% | +$974 | ﹤0.01% | 6227 |
|
|
2022
Q2 | $1K | Sell |
1,222
-10,328
| -89% | -$16.9K | ﹤0.01% | 6335 |
|
|
2022
Q1 | $25K | Buy |
11,550
+2,292
| +25% | +$6.14K | ﹤0.01% | 6020 |
|
|
2021
Q4 | $83K | Buy |
9,258
+487
| +6% | +$6.39K | ﹤0.01% | 5759 |
|
|
2021
Q3 | $146K | Buy |
8,771
+685
| +8% | +$11.8K | ﹤0.01% | 5381 |
|
|
2021
Q2 | $168K | Sell |
8,086
-1,434
| -15% | -$27.1K | ﹤0.01% | 5321 |
|
|
2021
Q1 | $179K | Buy |
9,520
+3,377
| +55% | +$72.9K | ﹤0.01% | 5191 |
|
|
2020
Q4 | $135K | Buy |
6,143
+1,056
| +21% | +$22K | ﹤0.01% | 4925 |
|
|
2020
Q3 | $103K | Buy |
5,087
+590
| +13% | +$15.3K | ﹤0.01% | 4673 |
|
|
2020
Q2 | $162K | Buy |
4,497
+1,868
| +71% | +$78.2K | ﹤0.01% | 4360 |
|
|
2020
Q1 | $86K | Sell |
2,629
-5,789
| -69% | -$234K | ﹤0.01% | 4564 |
|
|
2019
Q4 | $230K | Buy |
8,418
+7,522
| +840% | +$129K | ﹤0.01% | 4604 |
|
|
2019
Q3 | $10K | Buy |
+896
| New | +$8.45K | ﹤0.01% | 5496 |
|
JP Morgan Chase's APLT Position: Q1 2026 in Review
JP Morgan Chase sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 12,064 shares — an estimated $1.21K sold.
JP Morgan Chase first reported a position in APLT in Q3 2019 and held it in 26 quarters. The position peaked at $1.22M in Q1 2024. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.
- JP Morgan Chase reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 12,064 Applied Therapeutics shares in Q1 2026, an estimated $1.21K.
- JP Morgan Chase first reported a position in Applied Therapeutics in Q3 2019 and held it in 26 quarters.
- JP Morgan Chase's Applied Therapeutics position peaked at $1.22M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.